Latest Clinical Trials
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 17, 2026)
PHASE1, PHASE2 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer M.D. Anderson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer National Cancer Institute (NCI) NA
RECRUITING
(Sep 1, 2026)
PHASE1 Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma H. Lee Moffitt Cancer Center and Research Institute NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Fusion Pharmaceuticals Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) National Cancer Institute (NCI) NA
RECRUITING
(Aug 14, 2026)
PHASE1, PHASE2 Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) AstraZeneca NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors University Health Network, Toronto NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
COMPLETED
(Aug 1, 2026)
PHASE2 Olaparib With Ceralasertib in Recurrent Osteosarcoma Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd Gustave Roussy, Cancer Campus, Grand Paris NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer Dana-Farber Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE1 Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) University of Michigan Rogel Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Pembrolizumab, Olaparib, and Temozolomide for People With Glioma Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma National Cancer Institute (NCI) NA
TERMINATED
(Jul 1, 2026)
PHASE2 Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations Rana McKay, MD NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Pembro With Radiation With or Without Olaparib Zin W Myint NA
RECRUITING
(Jul 1, 2026)
PHASE2 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib University of Colorado, Denver NA
RECRUITING
(Jul 1, 2026)
PHASE2 Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer University of Colorado, Denver NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer University Health Network, Toronto NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors University Health Network, Toronto NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) Merck Sharp & Dohme LLC NA
COMPLETED
(Jun 1, 2026)
PHASE2 Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib AstraZeneca NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation National Cancer Institute (NCI) NA
RECRUITING
(Jun 1, 2026)
PHASE2 Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Fundación de investigación HM NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer Shandong University NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer Prof Gordon Jayson NA
COMPLETED
(Jun 1, 2026)
PHASE2 Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Northwestern University NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer Gruppo Oncologico del Nord-Ovest NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers University of Colorado, Denver NA
COMPLETED
(May 1, 2026)
PHASE2 Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer Daewoong Pharmaceutical Co. LTD. NA
RECRUITING
(May 1, 2026)
PHASE1 Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Selumetinib and Olaparib in Solid Tumors M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer University of Pennsylvania NA
COMPLETED
(Apr 1, 2026)
PHASE2 Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors Rahul Aggarwal NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations Academic and Community Cancer Research United NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours Vastra Gotaland Region NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma Memorial Sloan Kettering Cancer Center NA
COMPLETED
(Apr 1, 2026)
PHASE2 Study of LP-184 in Patients With Advanced Solid Tumors Lantern Pharma Inc. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Medical College of Wisconsin NA
COMPLETED
(Mar 1, 2026)
PHASE2 Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) University of Michigan Rogel Cancer Center NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. SOLTI Breast Cancer Research Group NA
COMPLETED
(Mar 1, 2026)
PHASE2 QLS5132 Combination Therapy in Advanced Solid Tumors Qilu Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 
